Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome
To study clinical significance of von Willebrand factor antigen (WFA) in antiphospholipid syndrome and systemic lupus erythematosus (SLE). Material and methods. Serum concentration of WFA was determined with immune-enzyme assay in 21 pts with primary APS (PAPS), 39 SLE pts with APS, 68 SLE pts and 5...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2004-08-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849398556362801152 |
|---|---|
| author | A A Novikov E N Alexandrova T V Popkova T M Reshetnyak N G Klyukvina D S Novikova LB Slitivelband A A Baranov |
| author_facet | A A Novikov E N Alexandrova T V Popkova T M Reshetnyak N G Klyukvina D S Novikova LB Slitivelband A A Baranov |
| author_sort | A A Novikov |
| collection | DOAJ |
| description | To study clinical significance of von Willebrand factor antigen (WFA) in antiphospholipid syndrome and systemic lupus erythematosus (SLE). Material and methods. Serum concentration of WFA was determined with immune-enzyme assay in 21 pts with primary APS (PAPS), 39 SLE pts with APS, 68 SLE pts and 56 healthy donors. Results. WFA level in PAPS, SLE+APS and SLE was significantly higher than in donors. WFA concentration in serum of SLE pts without APS significantly exceeded that in PAPS. WFA concentration elevation was revealed in 52,4% of PAPS, 56,4% SLE+APS and 73,5% SLE pts. There was no association between WFA level, thromboses and obstetric pathology in PAPS and SLE. WFA concentration increase in SLE with APS correlated with IgM anticardiolipin antibodies and SLEDAI activity index (p<0,05), in SLE - with SLEDAI and ECLAM activity indices (p<0,05). WFA level in SLE pts with renal disease was significantly higher than in SLE pts without renal disease. There was a direct correlation between WFA level and ESR (p<0,05) so as with CRP (p<0,05) in SLE. There were no significant differences of WFA level in SLE pts with and without atherosclerotic plaques. WFA level did not correlate with intima-media complex thickness. Conclusion. Development of immunopathological processin SLE and APS is associated with WFA hyper production. WFA elevated level reflects inflammatory activity of the disease in SLE but is not associated with presence of thrombotic and atherothrombotic complications in APS. |
| format | Article |
| id | doaj-art-dbf9cb2c294346dc914211fc4faf4b4e |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2004-08-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-dbf9cb2c294346dc914211fc4faf4b4e2025-08-20T03:38:34ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922004-08-01424353810.14412/1995-4484-2004-799876Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndromeA A NovikovE N AlexandrovaT V PopkovaT M ReshetnyakN G KlyukvinaD S NovikovaLB SlitivelbandA A BaranovTo study clinical significance of von Willebrand factor antigen (WFA) in antiphospholipid syndrome and systemic lupus erythematosus (SLE). Material and methods. Serum concentration of WFA was determined with immune-enzyme assay in 21 pts with primary APS (PAPS), 39 SLE pts with APS, 68 SLE pts and 56 healthy donors. Results. WFA level in PAPS, SLE+APS and SLE was significantly higher than in donors. WFA concentration in serum of SLE pts without APS significantly exceeded that in PAPS. WFA concentration elevation was revealed in 52,4% of PAPS, 56,4% SLE+APS and 73,5% SLE pts. There was no association between WFA level, thromboses and obstetric pathology in PAPS and SLE. WFA concentration increase in SLE with APS correlated with IgM anticardiolipin antibodies and SLEDAI activity index (p<0,05), in SLE - with SLEDAI and ECLAM activity indices (p<0,05). WFA level in SLE pts with renal disease was significantly higher than in SLE pts without renal disease. There was a direct correlation between WFA level and ESR (p<0,05) so as with CRP (p<0,05) in SLE. There were no significant differences of WFA level in SLE pts with and without atherosclerotic plaques. WFA level did not correlate with intima-media complex thickness. Conclusion. Development of immunopathological processin SLE and APS is associated with WFA hyper production. WFA elevated level reflects inflammatory activity of the disease in SLE but is not associated with presence of thrombotic and atherothrombotic complications in APS.https://rsp.mediar-press.net/rsp/article/view/936von willebrand factor antigenantiphospholipid syndromesystemic lupus erythematosus |
| spellingShingle | A A Novikov E N Alexandrova T V Popkova T M Reshetnyak N G Klyukvina D S Novikova LB Slitivelband A A Baranov Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome Научно-практическая ревматология von willebrand factor antigen antiphospholipid syndrome systemic lupus erythematosus |
| title | Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome |
| title_full | Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome |
| title_fullStr | Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome |
| title_full_unstemmed | Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome |
| title_short | Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome |
| title_sort | von willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome |
| topic | von willebrand factor antigen antiphospholipid syndrome systemic lupus erythematosus |
| url | https://rsp.mediar-press.net/rsp/article/view/936 |
| work_keys_str_mv | AT aanovikov vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome AT enalexandrova vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome AT tvpopkova vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome AT tmreshetnyak vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome AT ngklyukvina vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome AT dsnovikova vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome AT lbslitivelband vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome AT aabaranov vonwillebrandfactorantigeninsystemiclupuserythematosusandantiphospholipidsyndrome |